The "Sharp" blade against HIF-mediated metastasis

Cell Cycle

Volumn 11, Issue 24, 2012, Pages 4530-4535

  Amelio, Ivano ^a,b   Melino, Gerry ^a,b,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Angiogenesis; Breast cancer; Cancer metabolism; HIF; Hypoxia; Metastasis; p63; Sharp1; VHL

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROGESTERONE RECEPTOR; PROTEIN; SHARP 1 PROTEIN; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CIRCADIAN RHYTHM; GENE OVEREXPRESSION; HUMAN; METASTASIS; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 84871496171     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22820     Document Type: Review

References (141)

1. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9:302-12; PMID:19308069; http://dx.doi.org/10.1038/nrc2627.
2. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008; 5:206-19; PMID:18253104; http://dx.doi.org/10.1038/ ncponc1066.
3. Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer? Cell Death Differ 2011; 18:1470-7; PMID:21617693; http://dx.doi.org/10. 1038/cdd.2011.60.
4. Eckert MA, Yang J. Targeting invadopodia to block breast cancer metastasis. Oncotarget 2011; 2:562-8; PMID:21725138.
5. Iaccarino I, Martins LM. Therapeutic targets in cancer cell metabolism and death. Cell Death Differ 2011; 18:565-70; PMID:21212794; http://dx.doi.org/10.1038/cdd.2010.174.
6. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394:485-90; PMID:9697772; http://dx.doi.org/ 10.1038/28867.
7. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009; 106:2353-8; PMID:19168635; http://dx.doi.org/10.1073/pnas.0812801106.
8. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009; 106:17910-5; PMID:19805192; http://dx.doi.org/10.1073/pnas.0909353106.
9. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021.
10. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15:167-70;PMID:19249675; http://dx.doi.org/10.1016/j.ccr.2009.02.007.
11. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 2010; 17:499-512; PMID:19834490; http://dx.doi.org/10.1038/ cdd.2009.152.
12. Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca T, Ziparo E, et al. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ 2011; 18:1024-35; PMID:21233846; http://dx.doi.org/10.1038/cdd.2010.175.
13. Zhang Y, Chen M, Venugopal S, Zhou Y, Xiang W, Li YH, et al. Isthmin exerts pro-survival and deathpromoting effect on endothelial cells through alphavbeta5 integrin depending on its physical state. Cell Death Dis 2011; 2:e153; PMID:21544092; http://dx.doi.org/10.1038/cddis.2011.37.
14. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11:407-20; PMID:17482131; http://dx.doi.org/10.1016/j.ccr.2007.04.001.
15. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007; 12:230-8; PMID:17785204; http://dx.doi.org/10.1016/j.ccr.2007.08.004.
16. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011; 145:732-44; PMID:21620138; http://dx.doi.org/10.1016/j.cell.2011.03.054.
17. Zhang N, Fu Z, Linke S, Chicher J, Gorman JJ, Visk D, et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab 2010; 11:364-78; PMID:20399150; http://dx.doi.org/10. 1016/j.cmet.2010.03.001.
18. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011; 18:465-78; PMID:20885442; http://dx.doi.org/ 10.1038/cdd.2010.119.
19. Liu X, Hajnóczky G. Altered fusion dynamics underlie unique morphological changes in mitochondria during hypoxia-reoxygenation stress. Cell Death Differ 2011; 18:1561-72; PMID:21372848; http://dx.doi.org/10.1038/cdd. 2011.13.
20. Ben Mosbah I, Alfany-Fernández I, Martel C, Zaouali MA, Bintanel-Morcillo M, Rimola A, et al. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis 2010; 1:e52; PMID:21364657; http://dx.doi.org/10.1038/cddis.2010.29.
21. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387-94; PMID:12067980.
22. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004; 24:2875-89; PMID:15024076; http: //dx.doi .org/10.1128/MCB.24.7.2875-2889.2004.
23. Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 2010; 17:551-61; PMID:19798106; http://dx.doi.org/10.1038/cdd.2009.141.
24. Morizot A, Mérino D, Lalaoui N, Jacquemin G, Granci V, Iessi E, et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2011; 18:700-11; PMID:21072058; http://dx.doi.org/10. 1038/cdd.2010.144.
25. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, et al. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 2006; 66:3567-75; PMID:16585181; http://dx.doi.org/10.1158/0008-5472.CAN- 05-2670.
26. Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell 2010; 17:319-32; PMID:20385358; http://dx.doi.org/10.1016/j.ccr. 2010.02.030.
27. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011; 43:811-22; PMID:21884981; http://dx.doi.org/10.1016/ j.molcel.2011.07.012.
28. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelialmesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis 2011; 2:e179; PMID:21734725; http://dx.doi.org/10.1038/cddis.2011.61.
29. Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY) 2010; 2:735-41; PMID:20975209.
30. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222-6; PMID:16642001; http://dx.doi.org/10.1038/nature04695.
31. Wong CC, Gilkes DM, Zhang H, Chen J, Wei H, Chaturvedi P, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci USA 2011; 108:16369-74; PMID:21911388; http://dx.doi.org/10.1073/pnas.1113483108.
32. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012; 31:1757-70; PMID:21860410; http://dx.doi.org/10.1038/onc.2011.365.
33. Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression. J Cell Biol 2011; 192:83-99; PMID:21220510; http://dx.doi.org/10.1083/jcb.201004145.
34. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, et al. SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 2012; 487:380-4; PMID:22801492; http://dx.doi.org/10.1038/nature11207.
35. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12:9-22; PMID:22169972.
36. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4; PMID:7539918; http://dx.doi.org/10.1073/pnas. 92.12.5510.
37. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11:72-82; PMID:9000051; http://dx.doi.org/10.1101/gad.11.1.72.
38. Flamme I, Fröhlich T, von Reutern M, Kappel A, Damert A, Risau W. HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev 1997; 63:51-60; PMID:9178256; http://dx.doi.org/10.1016/S0925-4773(97)00674-6.
39. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 1997; 94:4273-8; PMID:9113979; http://dx.doi.org/10.1073/pnas.94.9.4273.
40. Hogenesch JB, Chan WK, Jackiw VH, Brown RC, Gu YZ, Pray-Grant M, et al. Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J Biol Chem 1997; 272:8581-93; PMID:9079689; http://dx.doi.org/10.1074/jbc.272.13.8581.
41. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8:131-41; PMID:16098466; http://dx.doi.org/10.1016/j.ccr.2005.07.003.
42. Ousset M, Bouquet F, Fallone F, Biard D, Dray C, Valet P, et al. Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: Role in the physiopathology of the disease. Cell Cycle 2010; 9:2814-22; PMID:20676049; http://dx.doi.org/10.4161/cc.9.14.12253.
43. Franovic A, Lee S. HIF-2alpha: many cancers, one engine? Cell Cycle 2010; 9:859-60; PMID:20348840; http://dx.doi.org/10.4161/cc.9.5.11183.
44. Hwang AB, Lee SJ. Regulation of life span by mitochondrial respiration: the HIF-1 and ROS connection. Aging (Albany NY) 2011; 3:304-10; PMID:21389351.
45. Kaelin WG Jr., Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30:393-402; PMID:18498744; http://dx.doi.org/10.1016/j.molcel.2008.04.009.
46. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res 2006; 66:8814-21; PMID:16951198; http://dx.doi.org/10.1158/0008-5472.CAN-05-4598.
47. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 2008; 8:865-73; PMID:18923434; http://dx.doi.org/10. 1038/nrc2502.
48. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002; 1:247-55; PMID:12086861; http://dx.doi.org/10.1016/S1535-6108(02)00044-2.
49. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002; 1:237-46; PMID:12086860; http://dx.doi.org/10.1016/S1535-6108(02) 00043-0.
50. Badiola N, Penas C, Miñano-Molina A, Barneda-Zahonero B, Fadó R, Sánchez-Opazo G, et al. Induction of ER stress in response to oxygen-glucose deprivation of cortical cultures involves the activation of the PERK and IRE-1 pathways and of caspase-12. Cell Death Dis 2011; 2:e149; PMID:21525936; http://dx.doi.org/10.1038/cddis.2011.31.
51. Roe JS, Kim HR, Hwang IY, Ha NC, Kim ST, Cho EJ, et al. Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation. Cell Cycle 2011; 10:3920-8; PMID:22071692; http://dx.doi.org/ 10.4161/cc.10.22.18096.
52. Majmundar AJ, Wong WJ, Simon MC. Hypoxiainducible factors and the response to hypoxic stress. Mol Cell 2010; 40:294-309; PMID:20965423; http://dx.doi.org/10.1016/j.molcel.2010.09.022.
53. Guitart AV, Debeissat C, Hermitte F, Villacreces A, Ivanovic Z, Boeuf H, et al. Very low oxygen concentration (0.1%) reveals two FDCP-Mix cell subpopulations that differ by their cell cycling, differentiation and p27KIP1 expression. Cell Death Differ 2011; 18:174-82; PMID:20671746; http://dx.doi.org/10.1038/cdd.2010.85.
54. Tiede LM, Cook EA, Morsey B, Fox HS. Oxygen matters: tissue culture oxygen levels affect mitochondrial function and structure as well as responses to HIV viroproteins. Cell Death Dis 2011; 2:e246; PMID:22190005; http://dx.doi.org/10.1038/cddis.2011.128.
55. Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, et al. Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget 2011; 2:1191-202; PMID:22202117.
56. Nardinocchi L, Puca R, D'Orazi G. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging (Albany NY) 2011; 3:33-43; PMID:21248371.
57. Chen ZX, Pervaiz S. Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ 2010; 17:408-20; PMID:19834492; http://dx.doi.org/10.1038/cdd.2009.132.
58. Russo R, Berliocchi L, Adornetto A, Varano GP, Cavaliere F, Nucci C, et al. Calpain-mediated cleavage of Beclin-1 and autophagy deregulation following retinal ischemic injury in vivo. Cell Death Dis 2011; 2:e144; PMID:21490676; http://dx.doi.org/10.1038/cddis.2011.29.
59. Darnell JE Jr. STAT3, HIF-1, glucose addiction and Warburg effect. Aging (Albany NY) 2010; 2:890-1; PMID:21149895.
60. Demaria M, Giorgi C, Lebiedzinska M, Esposito G, D'Angeli L, Bartoli A, et al. A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) 2010; 2:823-42; PMID:21084727.
61. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, et al. Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) 2010; 2:185-99; PMID:20442453.
62. Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell 2010; 40:509-20; PMID:21095582; http://dx.doi.org/10.1016/j.molcel.2010.10. 030.
63. Mitchell GC, Fillinger JL, Sittadjody S, Avila JL, Burd R, Limesand KH. IGF1 activates cell cycle arrest following irradiation by reducing binding of ΔNp63 to the p21 promoter. Cell Death Dis 2010; 1:e50; PMID:21480565; http://dx.doi.org/10.1038/cddis.2010.28.
64. Li X, Kumar A, Zhang F, Lee C, Li Y, Tang Z, et al. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 2010; 1:309-14; PMID:20871734.
65. Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011; 71:4640-52; PMID:21712410; http://dx.doi.org/10.1158/0008-5472.CAN-10-3320.
66. Mazumdar J, O'Brien WT, Johnson RS, LaManna JC, Chavez JC, Klein PS, et al. O2 regulates stem cells through Wnt/ â -catenin signalling. Nat Cell Biol 2010; 12:1007-13; PMID:20852629; http://dx.doi.org/10.1038/ncb2102.
67. Ko CY, Tsai MY, Tseng WF, Cheng CH, Huang CR, Wu JS, et al. Integration of CNS survival and differentiation by HIF2β. Cell Death Differ 2011; 18:1757-70; PMID:21546908; http://dx.doi.org/10.1038/cdd.2011.44.
68. Torii S, Goto Y, Ishizawa T, Hoshi H, Goryo K, Yasumoto K, et al. Pro-apoptotic activity of inhibitory PAS domain protein (IPAS), a negative regulator of HIF-1, through binding to pro-survival Bcl-2 family proteins. Cell Death Differ 2011; 18:1711-25; PMID:21546903; http://dx.doi.org/10.1038/cdd. 2011.47.
69. Mora-Castilla S, Tejedo JR, Hmadcha A, Cahuana GM, Martín F, Soria B, et al. Nitric oxide repression of Nanog promotes mouse embryonic stem cell differentiation. Cell Death Differ 2010; 17:1025-33; PMID:20075941; http://dx.doi.org/10.1038/cdd.2009.204.
70. Stacpoole SR, Bilican B, Webber DJ, Luzhynskaya A, He XL, Compston A, et al. Derivation of neural precursor cells from human ES cells at 3% O(2) is efficient, enhances survival and presents no barrier to regional specification and functional differentiation. Cell Death Differ 2011; 18:1016-23; PMID:21274009; http://dx.doi.org/10.1038/cdd.2010.171.
71. Casati A, Frascoli M, Traggiai E, Proietti M, Schenk U, Grassi F. Cell-autonomous regulation of hematopoietic stem cell cycling activity by ATP. Cell Death Differ 2011; 18:396-404; PMID:20798687; http://dx.doi.org/10.1038/ cdd.2010.107.
72. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68:7846-54; PMID:18829540; http://dx.doi.org/10.1158/0008-5472.CAN-08-1942.
73. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11:670-7; PMID:20706219; http://dx.doi.org/10.1038/embor.2010.117.
74. Manisterski M, Golan M, Amir S, Weisman Y, Mabjeesh NJ. Hypoxia induces PTHrP gene transcription in human cancer cells through the HIF-2α. Cell Cycle 2010; 9:3723-9; PMID:20890122; http://dx.doi.org/10.4161/cc.9.18.12931.
75. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8:967-75; PMID:18987634; http://dx.doi.org/10.1038/ nrc2540.
76. Li Q, Li H, Roughton K, Wang X, Kroemer G, Blomgren K, et al. Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell Death Dis 2010; 1:e56; PMID:21364661; http://dx.doi.org/10.1038/cddis.2010.33.
77. Lemarie A, Huc L, Pazarentzos E, Mahul-Mellier AL, Grimm S. Specific disintegration of complex II succinate:ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction. Cell Death Differ 2011; 18:338-49; PMID:20706275; http://dx.doi.org/10.1038/cdd.2010.93.
78. Mongiardi MP, Stagni V, Natoli M, Giaccari D, D'Agnano I, Falchetti ML, et al. Oxygen sensing is impaired in ATM-defective cells. Cell Cycle 2011; 10:4311-20; PMID:22134239; http://dx.doi.org/10.4161/cc.10.24.18663.
79. Whelan KA, Reginato MJ. Surviving without oxygen: hypoxia regulation of mammary morphogenesis and anoikis. Cell Cycle 2011; 10:2287-94; PMID:21670595; http://dx.doi.org/10.4161/cc.10.14.16532.
80. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, et al. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 2004; 10:8554-60; PMID:15623639; http://dx.doi.org/10.1158/1078-0432.CCR-0946-03.
81. Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, et al. HIF-1alpha and HIF-2alpha are differentially regulated in vivo in neuroblastoma: high HIF-1alpha correlates negatively to advanced clinical stage and tumor vascularization. Clin Cancer Res 2009; 15:7130-6; PMID:19903792; http: //dx.doi.org/10.1158/1078-0432.CCR-09-0223.
82. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005; 11:1129-35; PMID:15709180.
83. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:7388-93; PMID:18094421; http://dx.doi.org/10.1158/1078-0432. CCR-07-0411.
84. Tomé M, López-Romero P, Albo C, Sepúlveda JC, Fernández-Gutiérrez B, Dopazo A, et al. miR-335 orchestrates cell proliferation, migration and differentiation in human mesenchymal stem cells. Cell Death Differ 2011; 18:985-95; PMID:21164520; http://dx.doi.org/10.1038/cdd. 2010.167.
85. Adam J, Ratcliffe PJ, Pollard PJ. Novel insights into FH-associated disease are KEAPing the lid on oncogenic HIF signalling. Oncotarget 2011; 2:820-1; PMID:22064867.
86. Kim WY, Oh SH, Woo JK, Hong WK, Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation- inducedstabilization of hypoxia-inducible factor-1alpha. Cancer Res 2009; 69:1624-32; PMID:19176399; http://dx.doi.org/10.1158/0008-5472.CAN-08-0505.
87. Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18:1815-24; PMID:21941372; http://dx.doi.org/10.1038/cdd.2011.120.
88. Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, et al. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stemlike characteristics in a hypoxic environment. Cell Death Differ 2010; 17:1211-20; PMID:20139893; http://dx.doi.org/10.1038/cdd.2010.6.
89. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187.
90. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15:678-85; PMID:18259193; http://dx.doi.org/10.1038/cdd.2008.21.
91. Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, et al. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci USA 2010; 107:14182-7; PMID:20660313; http://dx.doi.org/10.1073/pnas. 1001296107.
92. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515-33; PMID:20855962; http://dx.doi.org/10.4161/cc.9.17.12928.
93. Thangarajah H, Vial IN, Grogan RH, Yao D, Shi Y, Januszyk M, et al. HIF-1alpha dysfunction in diabetes. Cell Cycle 2010; 9:75-9; PMID:20016290; http://dx.doi.org/10.4161/cc.9.1.10371.
94. Fer N, Melillo G. The HIF-1α-c-Myc pathway and tumorigenesis: evading the apoptotic gate-keeper. Cell Cycle 2011; 10:3228; PMID:21971179; http://dx.doi.org/10.4161/cc.10.19.17049.
95. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67:563-72; PMID:17234764; http://dx.doi.org/10.1158/0008-5472.CAN-06-2701.
96. Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, et al. Differential activation and antagonistic function of HIF-alpha isoforms in macrophages are essential for NO homeostasis. Genes Dev 2010; 24:491-501; PMID:20194441; http://dx.doi.org/10.1101/gad.1881410.
97. Weidemann A, Krohne TU, Aguilar E, Kurihara T, Takeda N, Dorrell MI, et al. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia 2010; 58:1177-85; PMID:20544853.
98. Stockmann C, Kerdiles Y, Nomaksteinsky M, Weidemann A, Takeda N, Doedens A, et al. Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis. Proc Natl Acad Sci USA 2010; 107:4329-34; PMID:20142499; http://dx.doi.org/10.1073/pnas.0912766107.
99. Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G, et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011; 18:1628-39; PMID:21527937; http://dx.doi.org/10.1038/cdd.2011.42.
100. Qi J, Pellecchia M, Ronai ZA. The Siah2-HIF-FoxA2 axis in prostate cancer - new markers and therapeutic opportunities. Oncotarget 2010; 1:379-85; PMID:21037926.
101. Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 2010; 1:246-51; PMID:21152246.
102. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber HP, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6:485-95; PMID:15542432; http://dx.doi.org/10.1016/j.ccr.2004.09.026.
103. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441:437-43; PMID:16724055; http://dx.doi.org/10.1038/nature04871.
104. Buzdar AU. Medical oncology: Endocrine-therapyrelated symptoms and breast cancer. Nature reviews. Clin Oncol 2009; 6:309-10.
105. Yalcin-Ozuysal O, Fiche M, Guitierrez M, Wagner KU, Raffoul W, Brisken C. Antagonistic roles of Notch and p63 in controlling mammary epithelial cell fates. Cell Death Differ 2010; 17:1600-12; PMID:20379195; http://dx.doi.org/10. 1038/cdd.2010.37.
106. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010; 17:246-54; PMID:19730444; http://dx.doi.org/10.1038/cdd.2009.117.
107. Dever SM, Golding SE, Rosenberg E, Adams BR, Idowu MO, Quillin JM, et al. Mutations in the BRCT binding site of BRCA1 result in hyperrecombination. Aging (Albany NY) 2011; 3:515-32; PMID:21666281.
108. Harris JL, Khanna KK. BRCA1 A-complex fine tunes repair functions of BRCA1. Aging (Albany NY) 2011; 3:461-3; PMID:21805697.
109. Riesterer O, Milas L, Ang KK. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007; 25:4075-83; PMID:17827456; http://dx.doi.org/10.1200/JCO.2007.11.8497.
110. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates pacli-taxel- induced apoptosis in breast cancer cells. Cell Death Differ 2010; 17:1624-35; PMID:20431602; http://dx.doi.org/10. 1038/cdd.2010.41.
111. Li QQ, Chen ZQ, Cao XX, Xu JD, Xu JW, Chen YY, et al. Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial-mesenchymal transition of breast cancer cells. Cell Death Differ 2011; 18:16-25; PMID:20798686; http://dx.doi.org/10.1038/cdd.2010.103.
112. Liu B, Wen JK, Li BH, Fang XM, Wang JJ, Zhang YP, et al. Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis 2011; 2:e185; PMID:21796157; http://dx.doi.org/10.1038/cddis.2011.64.
113. Rossner MJ, Oster H, Wichert SP, Reinecke L, Wehr MC, Reinecke J, et al. Disturbed clockwork resetting in Sharp-1 and Sharp-2 single and double mutant mice. PLoS One 2008; 3:e2762; PMID:18648504; http://dx.doi.org/10.1371/journal. pone.0002762.
114. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192:209-18; PMID:21263025; http://dx.doi.org/10.1083/jcb.201009059.
115. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011; 18:271-81; PMID:20689556; http://dx.doi.org/10.1038/cdd.2010.94.
116. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011; 2:e164; PMID:21614094; http://dx.doi.org/10.1038/ cddis.2011.48.
117. Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, Löschmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2011; 2:e243; PMID:22170099; http://dx.doi.org/10.1038/cddis.2011.129.
118. Gatta R, Dolfini D, Mantovani R. NF-Y joins E2Fs, p53 and other stress transcription factors at the apoptosis table. Cell Death Dis 2011; 2:e162; PMID:21614092; http://dx.doi.org/10.1038/cddis.2011.45.
119. Jiang M, Chiu SY, Hsu W. SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ 2011; 18:1005-15; PMID:21183956; http://dx.doi.org/10.1038/cdd.2010.168.
120. Antico Arciuch VG, Russo MA, Dima M, Kang KS, Dasrath F, Liao XH, et al. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2011; 2:1109-26; PMID:22190384.
121. Hill R, Madureira PA, Waisman DM, Lee PW. DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. Oncotarget 2011; 2:1094-108; PMID:22190353.
122. Napoli M, Girardini JE, Piazza S, Del Sal G. Wiring the oncogenic circuitry: Pin1 unleashes mutant p53. Oncotarget 2011; 2:654-6; PMID:21926448.
123. Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY) 2010; 2:924-35; PMID:21212465.
124. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467:986-90; PMID:20962848; http://dx.doi.org/10.1038/nature09459.
125. Beaudry VG, Jiang D, Dusek RL, Park EJ, Knezevich S, Ridd K, et al. Loss of the p53/p63 regulated desmosomal protein Perp promotes tumorigenesis. PLoS Genet 2010; 6:e1001168; PMID:20975948; http://dx.doi.org/10.1371/journal.pgen. 1001168.
126. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, et al. p53 directly transactivates Δ133p53 α, regulating cell fate outcome in response to DNA damage. Cell Death Differ 2011; 18:248-58; PMID:20689555; http://dx.doi.org/10.1038/cdd.2010.91.
127. Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr Y, Boukamp P, et al. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Dis 2010; 1:e74; PMID:21151771; http://dx.doi.org/ 10.1038/cddis.2010.49.
128. Borrelli S, Candi E, Hu B, Dolfini D, Ravo M, Grober OM, et al. The p63 target HBP1 is required for skin differentiation and stratification. Cell Death Differ 2010; 17:1896-907; PMID:20523354; http://dx.doi.org/10.1038/cdd.2010.59.
129. Lena AM, Cipollone R, Amelio I, Catani MV, Ramadan S, Browne G, et al. Skn-1a/Oct-11 and ΔNp63α exert antagonizing effects on human keratin expression. Biochem Biophys Res Commun 2010; 401:568-73; PMID:20888799; http://dx.doi.org/10.1016/j.bbrc.2010.09.102.
130. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2011; 2:1203-17; PMID:22203497.
131. Lane DP, Verma C, Fang CC. The p53 inducing drug dosage may determine quiescence or senescence. Aging (Albany NY) 2010; 2:748; PMID:21068468.
132. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 2011; 7:285-95; PMID:21445056; http://dx.doi.org/10.1038/ nchembio.546.
133. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18:1487-99; PMID:21760596; http://dx.doi.org/10.1038/cdd.2011.81.
134. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17:901-11; PMID:20379196; http://dx.doi.org/10.1038/cdd.2010.35.
135. Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration
136. Sayeed A, Meng Z, Luciani G, Chen LC, Bennington JL, Dairkee SH. Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediategrade primary breast cancer. Cell Death Dis 2010; 1:e53; PMID:21364658; http://dx.doi.org/10.1038/cddis.2010.30.
137. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137:87-98; PMID:19345189; http://dx.doi.org/10.1016/j.cell.2009.01.039.
138. Sato F, Bhawal UK, Kawamoto T, Fujimoto K, Imaizumi T, Imanaka T, et al. Basic-helix-loop-helix (bHLH) transcription factor DEC2 negatively regulates vascular endothelial growth factor expression. Genes Cells 2008; 13:131-44; PMID:18233956; http://dx.doi.org/10.1111/j.1365-2443.2007.01153.x.
139. Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010; 9:1722-8; PMID:20404562; http://dx.doi.org/10.4161/cc.9.9.11358.
140. Agostini M, Tucci P, Melino G. Cell death pathology: perspective for human diseases. Biochem Biophys Res Commun 2011; 414:451-5; PMID:21964290; http://dx.doi.org/10.1016/j.bbrc.2011.09.081.
141. Amelio I, Melino G, Knight RA. Cell death pathology: cross-talk with autophagy and its clinical implications. Biochem Biophys Res Commun 2011; 414:277-81; PMID:21963447; http://dx.doi.org/10.1016/j.bbrc.2011.09.080.